Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov;18(4):513-521.
doi: 10.1007/s10238-018-0520-7. Epub 2018 Jul 17.

Mixed-phenotype acute leukemia characteristics: first report from Iran

Behzad Poopak  1   2 , Adnan Khosravi  3 , Gholamreza Bahoush-Mehdiabadi  4 , Tahereh Madani  5 , Elahe Khodadi  5 , Zohreh Farahani  5 , Amir Ali Vahedi  5 , Gelareh Khosravipour  5 , Peyvand Poopak  5 , Amir Hossein Poopak  5
Affiliations

Mixed-phenotype acute leukemia characteristics: first report from Iran

Behzad Poopak et al. Clin Exp Med. 2018 Nov.

Erratum in

Abstract

Mixed-phenotype acute leukemia (MPAL) is the infrequent type of acute leukemia characterized by immunophenotypic and/or cytochemical features of both lineages, but the diagnosis of this disease still is a challenge. In this study, we analyzed immunophenotyping, cytochemistry and frequency of MPAL patients to better diagnosis of MPAL characteristics according to WHO 2016 criteria for the first time in Iran. In this retrospective study, 27 patients were diagnosed as MPAL based on WHO 2016 criteria during 2014-2017. Flow cytometric immunophenotyping was performed on PB and BM samples evaluation of different CD marker expressions in MPAL subsets. RT-PCR was performed for the analyses of BCR/ABL1 fusion in MPAL subsets. Among 27 cases, (70.4%) 19 cases were B + My, (22.22%) 6 cases were T + My, and 2 cases (7.40%) were B + T + My. CD34, CD19, HLA-DR, TdT, CD22, iMPO were positive in majority of B + My cases. CD45, iMPO, iCD3, CD7, CD2 and CD5 were positive in majority of T + My cases. HLA-DR, TdT, CD10, CD22, iCD79a, iMPO, CD45, iCD3, CD7, CD3, CD2, CD5 were positive in majority of B + T + My cases. BCR/ABL1 fusion was positive for 3 cases (11.1%) of p190 fusion and 2 cases (7.4%) of p210 fusion in B + My cases. WHO 2016 criteria are the current standard for diagnosing MPAL. Also, evaluation of TdT, CD2, CD5, CD7 expressions by flow cytometry in EGIL criteria is useful for the better diagnosis of MPAL subsets. In addition, evaluation of BCR/ABL1 and MLL rearrangements in patients should be part of standard work-up in MPAL.

Keywords: BCR/ABL1; Flow cytometry; Mixed-phenotype acute leukemia.

PubMed Disclaimer

References

    1. Wolach O, Stone RM. How I treat mixed-phenotype acute leukemia. Blood. 2015;125(16):2477–85. - DOI
    1. Golchin N, Khodadi E, Yaghooti SH, Jaseb K, Shahjahani M, Tavakolifar Y, et al. Immunophenotype, microRNA expression and cytogenetic characterization of acute leukemias of ambiguous lineage. Comp Clin Pathol. 2017;26(2):261–7. - DOI
    1. Getta BM, Roshal M, Zheng J, Park JH, Stein EM, Levine R, et al. Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning is associated with favorable outcomes in mixed phenotype acute leukemia. Biol Blood Marrow Transplant. 2017;23:1879–86. - DOI
    1. Kim HJ. Mixed-phenotype acute leukemia (MPAL) and beyond. Blood Res. 2016;51(4):215–6. - DOI
    1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51. - DOI

LinkOut - more resources